Interview with Sylvia Kang, Co-Founder and CEO at Home Healthcare Company: Mira

Quanovate Tech Inc. (Mira) is a San-Francisco-based company that provides healthcare products for more personal, accurate, and reliable home healthcare. It was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing.

The company’s first healthcare product for at-home testing — Mira — was released in 2018. It’s an AI-powered device that helps women to track their reproductive health from the comfort of their home. Mira is the only home testing product that can measure multiple hormones and track women’s health comprehensively with laboratory-grade accuracy.

Currently, the device tests for the concentrations of LH (luteinizing hormone), which is an indicator of ovulation; E3G (estrogen), which is a key component in understanding reproductive health; and PdG (the urine metabolite of progesterone), which confirms ovulation, and FSH (follicle-stimulating hormone) helping to evaluate fertility status and predict approaching menopause. hCG (human chorionic gonadotropin) is coming soon.
 
 

 

How did you come up with the idea for the company?

 
It’s not a secret that fertility issues are on rise and fertility rates are declining everywhere. The picture of motherhood is changing as well. Women are becoming mothers later in life choosing advanced education and career over parenting. I’m myself the example of so-called “postponed motherhood”. Many of my friends are on a similar journey.

When one close friend of mine started to try for a baby, she had no results after six months of trying. The doctor couldn’t find any problems. The existing fertility products didn’t help either as they didn’t tell give enough insights to be her guide. She eventually got pregnant through IUI.

This is a general and trending issue faced by more and more women today.

Scientifically, every woman is different. An accurate answer can only come from a personalized angle. I started Mira hoping to give women the accuracy of lab testing at home, easy to understand and actionable data to help them make the best decision.
 

How has the company evolved over the last couple of years?

 
We have been growing significantly so far. We have seen the Mira brand becoming more trustworthy to our customers. Starting from its launch in September 2018, Mira helped over 80,000 women worldwide reach their fertility goals. The company grows exponentially, attracting on average 20% more users each year.
At the same time, we are very hopeful for the coming years. We are constantly developing more test wands, which will be used with the same Mira analyzer, but for new purposes. So to say just recently we have significantly expanded the capabilities in at-home hormone testing by introducing the new Mira Ovum wands which aim to help women to track their FSH levels to predict approaching menopause.

Overall our goal is to give women a comprehensive, continuous, and accurate understanding of their health and take out any guesswork.
 

What can we hope to see from Mira in the future?

 
We’re planning to expand and deepen our B2B direction, meaning to have more partnerships and clinical trials with fertility clinics worldwide. Mira has recently finalized another trial with IVF patients in collaboration with Olive Fertility – one of the largest IVF clinics in Canada.

With Mira’s technology being the only one on the market meeting the strict requirements of IVF treatment, Mira aims to create a new standard of daily, at-home hormone monitoring across the whole spectrum of fertility treatments.